Hemerion

Hemerion Therapeutics is pioneering a disruptive photonic-based therapy for glioblastoma, a devastating brain cancer with no cure. Its platform combines a proprietary drug, Pentalafen®, with a laser-based device (Heliance Solution) to target and kill cancer cells during surgical resection. The company has generated promising early clinical data, received positive regulatory feedback from the FDA and European agencies, and is preparing for a pivotal clinical trial. Hemerion's approach aims to significantly improve survival and quality of life by seamlessly integrating into the current surgical workflow.

Proprietary drug-device combination platform integrating a photosensitizing drug (Pentalafen®) with an innovative photonic/laser system (Heliance Solution) for intraoperative photodynamic therapy.

Hemerion competes in the neuro-oncology space with other investigational therapies including tumor-treating fields (Novocure's Optune), novel immunotherapies, targeted agents, and other localized delivery systems. Its primary differentiation is the intraoperative, photonic-based mechanism designed to destroy residual microscopic disease immediately after resection, positioning it as a potential foundational treatment rather than a later-line option.